Oncotarget

Clinical Research Papers:

Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials

Claudia Marchetti, Francesca De Felice _, Innocenza Palaia, Angela Musella, Violante Di Donato, Maria Luisa Gasparri, Daniela Musio, Ludovico Muzii, Vincenzo Tombolini and Pierluigi Benedetti Panici

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:13221-13227. https://doi.org/10.18632/oncotarget.6507

Metrics: PDF 2218 views  |   HTML 2062 views  |   ?  


Abstract

Claudia Marchetti1,*, Francesca De Felice2,*, Innocenza Palaia1, Angela Musella1, Violante Di Donato1, Maria Luisa Gasparri1, Daniela Musio2, Ludovico Muzii1, Vincenzo Tombolini2, Pierluigi Benedetti Panici1

1Department of Obstetrics-Gynecological Sciences and Urological Sciences, Policlinico Umberto I “Sapienza” University of Rome, Viale del Policlinico, Rome 00161, Italy

2Department of Radiotherapy, Policlinico Umberto I “Sapienza” University of Rome, Viale Regina Elena, Rome 00161, Italy

*These authors contributed equally to this work

Correspondence to:

Francesca De Felice, e-mail: [email protected]

Keywords: bevacizumab, ovarian cancer, recurrent, survival, toxicity

Received: September 02, 2015     Accepted: November 10, 2015     Published: December 08, 2015

ABSTRACT

Background: To analyze the efficacy and toxicity of bevacizumab on survival outcomes in recurrent ovarian cancer.

Results: Bevacizumab was associated with significant improvement of PFS and OS compared with standard treatment with HRs of 0.53 (95% CI 0.44 − 0.63; p < 0.00001) and 0.87 (95% CI, 0.77 to 0.99; p = 0.03), respectively.

Bevacizumab increased the incidence of G3/G4 hypertension (RR 19.01, 95% CI 7.77 – 46.55; p < 0.00001), proteinuria (RR 17.31, 95% CI 5.42 − 55.25; p < 0.00001), arterial thromboembolic events (ATE) (RR 4.99, 95% CI 1.29 − 19.27; p = 0.02) and bleeding (RR 3.14, 95% CI 1.35 – 7.32; p = 0.008).

Materials and Methods: Three randomized phase III trials representing 1502 patients were identified.

Pooled hazard ratio (HR), odd ratio (OR), risk ratio (RR) with 95% confidence interval (CI) were calculated using fixed or random effects model.

Conclusions: Adding bevacizumab to standard chemotherapy improved ORR, PFS and OS, and it had a higher, but manageable, incidence of toxicities graded 3 to 4.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 6507